The dosage may vary as the treatment progresses, often starting at a low dose to adjust for tolerability
Benhamed F, Denechaud PD, Lemoine M, Robichon C, Moldes M, Bertrand-Michel J, Ratziu V, Serfaty L, Housset C, Capeau J, Girard J, Guillou H, Postic C (2012) The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans
By focusing on root-causes (nutrition, metabolism, digestion, activity) rather than purely symptom suppression, youre building a foundation for long-term health rather than short-term change
Maintenance Benefits continue accruing during months three through six, though the rate of visible change typically slows compared to the dramatic improvements of weeks seven through twelve